Related references
Note: Only part of the references are listed.Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
Michaela Patz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
CD40 stimulation sensitizes CLL cells to rituximab-induced cell death
M. Jak et al.
LEUKEMIA (2011)
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia
S. H. Tonino et al.
ONCOGENE (2011)
Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death
Josee Golay et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacological activation of the p53 pathway in haematological malignancies
Manujendra N. Saha et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia
S. H. Tonino et al.
LEUKEMIA (2010)
Ultrasensitive in situ visualization of active glucocerebrosidase molecules
Martin D. Witte et al.
NATURE CHEMICAL BIOLOGY (2010)
Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering
J. M. Tromp et al.
ONCOGENE (2010)
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Meike Vogler et al.
BLOOD (2009)
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Jan A. Burger et al.
BLOOD (2009)
Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Trevor W. Dennie et al.
CLINICAL THERAPEUTICS (2009)
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
Delfine Y. H. Hallaert et al.
BLOOD (2008)
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism
Andrew J. Steele et al.
BLOOD (2008)
Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
Gael Roue et al.
CLINICAL CANCER RESEARCH (2008)
Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling
Claire A. Walshe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Lysosomal membrane permeabilization in cell death
P. Boya et al.
ONCOGENE (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection
D. Y. H. Hallaert et al.
CELL DEATH AND DIFFERENTIATION (2007)
Cellular immune therapy for chronic lymphocytic leukemia
Arnon P. Kater et al.
BLOOD (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines
Sandra J. Strauss et al.
CANCER RESEARCH (2007)
Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes
R. Mous et al.
LEUKEMIA (2006)
Caspase-independent killing of Burkitt lymphoma cell lines by rituximab
I Daniels et al.
APOPTOSIS (2006)
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Paola Secchiero et al.
BLOOD (2006)
Lysosomes and autophagy in cell death control
G Kroemer et al.
NATURE REVIEWS CANCER (2005)
Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation
WJM Mackus et al.
LEUKEMIA (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of bid by multiple papain-like lysosomal cathepsins
T Cirman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
A Rosenwald et al.
BLOOD (2004)
CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack
AP Kater et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Role of the microenvironment in chronic lymphocytic leukaemia
F Caligaris-Cappio
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy
I Sturm et al.
CELL DEATH AND DIFFERENTIATION (2003)
Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption in tumor necrosis factor alpha-induced cell death
K Ono et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
CD20-mediated apoptosis: signalling through lipid rafts
JP Deans et al.
IMMUNOLOGY (2002)
CD20-induced B cell death can bypass mitochondria and caspase activation
LE van der Kolk et al.
LEUKEMIA (2002)
Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
MA Ghetie et al.
BLOOD (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells
RR Furman et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
